Final answer:
The non-dihydropyridine calcium channel blocker used for kidney stones is potentially Verapamil, though it's an off-label use. Verapamil generally treats cardiovascular conditions and may assist in kidney stone management by affecting urinary tract dynamics. Other common treatments for kidney stones include medication, lithotripsy, or ureteral stenting.
Step-by-step explanation:
The non-dihydropyridine calcium channel blocker (CCB) that can be used to treat kidney stones is Verapamil (Calan, Verelan). While not its primary indication, verapamil may have an off-label use in certain circumstances related to kidney stone passage. Kidney stones can cause severe pain and lead to significant complications. Management strategies include medication to control pain, promote stone passage, and prevent new stone formation. Typically, drugs such as thiazides, potassium citrate, magnesium citrate, and allopurinol are used, depending on the cause of the stone.
When considering cardiovascular effects, non-dihydropyridine CCBs like verapamil are primarily used to treat high blood pressure, angina, and certain arrhythmias. They work by relaxing the blood vessels and reducing the heart's workload. This mechanism, while primarily cardiovascular, may influence the dynamics of the urinary tract and assist in kidney stone management. However, the direct use of verapamil or any CCBs in treating kidney stones is less common than other treatments such as lithotripsy or the insertion of a ureteral stent. Consultation with a healthcare provider is essential to determine the appropriate therapy.